Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2025.101080
Christina Quell , Wolfgang G. Kunz , Viktoria Blumenberg , Kai Rejeski , Veit L. Bücklein , Maria Ingenerf , Christian Schmidt , Gabriel T. Sheikh , Matthias Brendel , Jens Ricke , Michael von Bergwelt-Baildon , Marion Subklewe , Michael Winkelmann
Purpose
Chimeric antigen receptor T-cell (CART) therapy targeting CD19 is effective for relapsed/refractory (r/r) lymphoma. As part of the lymphatic system, the spleen might influence CART outcomes. We examined how spleen volume (SV) and its changes affect progression-free (PFS) and overall survival (OS).
Methods
Patients with baseline (BL) and 30-day follow-up (FU1) (PET)/CT scans were included. Spleens were 3D-segmented, and volume change (SVC) from BL to FU1 was calculated. Treatment response, overall response rate, and PFS were evaluated by Lugano criteria.
Results
Among 68 patients, responders had a significantly greater SVC decrease from BL to FU1 than non-responders (p = 0.001). Those with baseline splenic involvement (SIBL) showed a smaller, non-significant SVCBL to FU1 decrease (p = 0.056). Survival analysis showed significant differences in OS (167 vs. 390 days, p = 0.040) and PFS (79 vs. 327 days, p = 0.008) based on median SVCBL to FU1. In combination with SIBL, SVC was significantly associated with PFS (p = 0.049), but not OS.
Conclusion
This study demonstrated that the early change in SV is associated with PFS and OS, regardless of splenic involvement and should be explored as a potential novel dynamic biomarker in the context of lymphoma patients receiving CART.
{"title":"Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapy","authors":"Christina Quell , Wolfgang G. Kunz , Viktoria Blumenberg , Kai Rejeski , Veit L. Bücklein , Maria Ingenerf , Christian Schmidt , Gabriel T. Sheikh , Matthias Brendel , Jens Ricke , Michael von Bergwelt-Baildon , Marion Subklewe , Michael Winkelmann","doi":"10.1016/j.ctarc.2025.101080","DOIUrl":"10.1016/j.ctarc.2025.101080","url":null,"abstract":"<div><h3>Purpose</h3><div>Chimeric antigen receptor T-cell (CART) therapy targeting CD19 is effective for relapsed/refractory (r/r) lymphoma. As part of the lymphatic system, the spleen might influence CART outcomes. We examined how spleen volume (SV) and its changes affect progression-free (PFS) and overall survival (OS).</div></div><div><h3>Methods</h3><div>Patients with baseline (BL) and 30-day follow-up (FU1) (PET)/CT scans were included. Spleens were 3D-segmented, and volume change (SVC) from BL to FU1 was calculated. Treatment response, overall response rate, and PFS were evaluated by Lugano criteria.</div></div><div><h3>Results</h3><div>Among 68 patients, responders had a significantly greater SVC decrease from BL to FU1 than non-responders (<em>p</em> = 0.001). Those with baseline splenic involvement (SI<sup>BL</sup>) showed a smaller, non-significant SVC<sup>BL to FU1</sup> decrease (<em>p</em> = 0.056). Survival analysis showed significant differences in OS (167 vs. 390 days, <em>p</em> = 0.040) and PFS (79 vs. 327 days, <em>p</em> = 0.008) based on median SVC<sup>BL to FU1</sup>. In combination with SI<sup>BL</sup>, SVC was significantly associated with PFS (<em>p</em> = 0.049), but not OS.</div></div><div><h3>Conclusion</h3><div>This study demonstrated that the early change in SV is associated with PFS and OS, regardless of splenic involvement and should be explored as a potential novel dynamic biomarker in the context of lymphoma patients receiving CART.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101080"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2026.101106
Xiaorong Su , Yiyin Weng , Yiqi Xiao , Lizhu Weng , Yanbin Zeng , Wanlong Lin , Wei Zhuang
Background
Liposomal doxorubicin hypersensitivity significantly affects breast cancer patients, with widely varying incidence rates (9 % to 46 %). Despite its efficacy, this condition poses a critical barrier to treatment due to the need for precise patient management and the absence of effective predictive biomarkers. This hypothesis-generating, exploratory study aimed to characterize plasma metabolic changes associated with hypersensitivity to liposomal doxorubicin in breast cancer patients, with the goal of identifying potential predictive biomarkers for future validation.
Methods
A retrospective metabolomic study was conducted on plasma samples from breast cancer patients treated with liposomal doxorubicin. Untargeted metabolomics was analyzed using LC–MS. Statistical methods, including Principal Component Analysis and Partial Least Squares Discriminant Analysis, were employed to identify significant metabolic changes, with a variable importance in projection score ≥1.0 and a p ≤ 0.05 as criteria for significance.
Results
Twelve breast cancer patients were included in this study (7 with immediate hypersensitivity). Differential metabolites revealed by the analysis included significant downregulation of 5,6-Dihydroxyeicosatrienoic acid (5,6-DHET) and kynurenic acid, along with marked upregulation of l-histidine. Pathway enrichment analysis highlighted dysregulation of key metabolic pathways, including the metabolism of phenylalanine, tyrosine, and β-alanine metabolism. Notably, the receiver operating characteristic curves demonstrated high diagnostic accuracy for several metabolites, including cytosine (AUC = 1.00), 5,6-DHET (AUC = 0.97), and l-histidine (AUC = 0.94), in predicting hypersensitivity.
Conclusion
Liposomal doxorubicin-induced hypersensitivity involves a metabolic network characterized by impaired anti-inflammatory responses (5,6-DHET/kynurenic acid depletion), histamine pathway activation (L-histidine accumulation), and aromatic amino acid dysregulation. These findings establish a novel biomarker framework for predicting hypersensitivity risk and provide mechanistic insights for targeted interventions.
{"title":"Metabolic signatures and predictive biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study","authors":"Xiaorong Su , Yiyin Weng , Yiqi Xiao , Lizhu Weng , Yanbin Zeng , Wanlong Lin , Wei Zhuang","doi":"10.1016/j.ctarc.2026.101106","DOIUrl":"10.1016/j.ctarc.2026.101106","url":null,"abstract":"<div><h3>Background</h3><div>Liposomal doxorubicin hypersensitivity significantly affects breast cancer patients, with widely varying incidence rates (9 % to 46 %). Despite its efficacy, this condition poses a critical barrier to treatment due to the need for precise patient management and the absence of effective predictive biomarkers. This hypothesis-generating, exploratory study aimed to characterize plasma metabolic changes associated with hypersensitivity to liposomal doxorubicin in breast cancer patients, with the goal of identifying potential predictive biomarkers for future validation.</div></div><div><h3>Methods</h3><div>A retrospective metabolomic study was conducted on plasma samples from breast cancer patients treated with liposomal doxorubicin. Untargeted metabolomics was analyzed using LC–MS. Statistical methods, including Principal Component Analysis and Partial Least Squares Discriminant Analysis, were employed to identify significant metabolic changes, with a variable importance in projection score ≥1.0 and a <em>p</em> ≤ 0.05 as criteria for significance.</div></div><div><h3>Results</h3><div>Twelve breast cancer patients were included in this study (7 with immediate hypersensitivity). Differential metabolites revealed by the analysis included significant downregulation of 5,6-Dihydroxyeicosatrienoic acid (5,6-DHET) and kynurenic acid, along with marked upregulation of <span>l</span>-histidine. Pathway enrichment analysis highlighted dysregulation of key metabolic pathways, including the metabolism of phenylalanine, tyrosine, and β-alanine metabolism. Notably, the receiver operating characteristic curves demonstrated high diagnostic accuracy for several metabolites, including cytosine (AUC = 1.00), 5,6-DHET (AUC = 0.97), and <span>l</span>-histidine (AUC = 0.94), in predicting hypersensitivity.</div></div><div><h3>Conclusion</h3><div>Liposomal doxorubicin-induced hypersensitivity involves a metabolic network characterized by impaired anti-inflammatory responses (5,6-DHET/kynurenic acid depletion), histamine pathway activation (L-histidine accumulation), and aromatic amino acid dysregulation. These findings establish a novel biomarker framework for predicting hypersensitivity risk and provide mechanistic insights for targeted interventions.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101106"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aims to establish the level of knowledge, attitudes, and practices (KAP) of healthcare professionals towards Marjolin’s ulcers prevention.
Methods
A descriptive cross-sectional study was conducted among healthcare professionals of a Nigerian Teaching Hospital. A validated self-administered questionnaire was used to collect data with specific sections on knowledge, attitude, and practices of healthcare workers on Marjolin’s ulcer prevention. Data analysis was done using descriptive statistics. Association between KAP and demographic characteristics was tested using the Chi-square test. Binary logistic regression was performed to identify factors associated with KAP, and statistical significance was considered at P < 0.05.
Results
Data from 254 participants were analyzed. Mean age of the respondents was 34.6 ± 10.1 years. Majority of the respondents were female 157 (61.8%), with 97 (38.2%) males, and a male to female ratio of 1:1.6. Most respondents were Nurses, 85 (33.5%). Mean score of the knowledge scale was 3.52, with mean scores of the latency period, childhood Marjolin’s ulcer, traumatic ulcer as precursor lesions 2.63, 2.02, and 2.49 respectively. 21.9% (49) will decline skin grafting. Bivariate analysis showed that gender and knowledge were significantly associated with practice (χ² = 4.900, p = 0.027; χ² = 11.148, p = 0.001). Logistic regression analysis indicated that males had higher odds of good practice compared to females (AOR = 2.034; 95% CI: 1.065–3.887; p = 0.032).
Conclusions
Improved practices towards Marjolin’s ulcer prevention require focused educational programmes, enhanced donor-site aesthetic appearance, and adoption of skin substitutes to assist healing of chronic wounds.
{"title":"Knowledge, attitude, and practice of healthcare professionals towards the prevention of Marjolin’s ulcer in an African suburban tertiary care institution: A cross-sectional study","authors":"Olakunle Fatai Babalola , Adedayo Idris Salawu , Adeniyi Steven Hassan , Innih Asuekome Kadiri , David Adekunle Onilede , Abiodun Idowu Okunlola , Kolawole Olubunmi Ogundipe","doi":"10.1016/j.ctarc.2025.101092","DOIUrl":"10.1016/j.ctarc.2025.101092","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to establish the level of knowledge, attitudes, and practices (KAP) of healthcare professionals towards Marjolin’s ulcers prevention.</div></div><div><h3>Methods</h3><div>A descriptive cross-sectional study was conducted among healthcare professionals of a Nigerian Teaching Hospital. A validated self-administered questionnaire was used to collect data with specific sections on knowledge, attitude, and practices of healthcare workers on Marjolin’s ulcer prevention. Data analysis was done using descriptive statistics. Association between KAP and demographic characteristics was tested using the Chi-square test. Binary logistic regression was performed to identify factors associated with KAP, and statistical significance was considered at <em>P</em> < 0.05.</div></div><div><h3>Results</h3><div>Data from 254 participants were analyzed. Mean age of the respondents was 34.6 ± 10.1 years. Majority of the respondents were female 157 (61.8%), with 97 (38.2%) males, and a male to female ratio of 1:1.6. Most respondents were Nurses, 85 (33.5%). Mean score of the knowledge scale was 3.52, with mean scores of the latency period, childhood Marjolin’s ulcer, traumatic ulcer as precursor lesions 2.63, 2.02, and 2.49 respectively. 21.9% (49) will decline skin grafting. Bivariate analysis showed that gender and knowledge were significantly associated with practice (χ² = 4.900, <em>p</em> = 0.027; χ² = 11.148, <em>p</em> = 0.001). Logistic regression analysis indicated that males had higher odds of good practice compared to females (AOR = 2.034; 95% CI: 1.065–3.887; <em>p</em> = 0.032).</div></div><div><h3>Conclusions</h3><div>Improved practices towards Marjolin’s ulcer prevention require focused educational programmes, enhanced donor-site aesthetic appearance, and adoption of skin substitutes to assist healing of chronic wounds.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101092"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2025.101060
Nouf Khalifa ALaqeel
Immunotherapy is currently one of the most promising fields for novel cancer treatments and discoveries. Scientists now understand how intricately our immune system interacts with cancer. The way we think about and treat cancer is evolving as a result of novel medicines that are made possible by our growing understanding of how the immune system functions. Treatment is now more tumor-specific and less toxic thanks to new cancer targeted medicines that employ therapeutic antibodies or tiny chemicals. Using ligand-targeted treatment to make targeting more precise and deliver bigger dosages of anti-cancer medication to tumor tissue is one of the most promising approaches to overcoming such obstacles. Optical biosensors are commonly used in clinical diagnostics, offering the advantage of continuous monitoring of biochemical reactions. The development of targeted medication delivery systems for a variety of illnesses, including cancer cells, is a potential area of nanomedicine. Researchers are concentrating on cancer cells because of their high rates of proliferation and resistance to conventional treatment techniques. .Lipid-based drug delivery employs nanoparticles to encapsulate and distribute medications to particular cells or tissues The present review is focused on personalized cancer vaccines are a promising immunotherapy targeting patient specific tumor neoantigens, and nanoparticles.
{"title":"Advances in personalized cancer vaccine to nanotechnology innovations","authors":"Nouf Khalifa ALaqeel","doi":"10.1016/j.ctarc.2025.101060","DOIUrl":"10.1016/j.ctarc.2025.101060","url":null,"abstract":"<div><div>Immunotherapy is currently one of the most promising fields for novel cancer treatments and discoveries. Scientists now understand how intricately our immune system interacts with cancer. The way we think about and treat cancer is evolving as a result of novel medicines that are made possible by our growing understanding of how the immune system functions. Treatment is now more tumor-specific and less toxic thanks to new cancer targeted medicines that employ therapeutic antibodies or tiny chemicals. Using ligand-targeted treatment to make targeting more precise and deliver bigger dosages of anti-cancer medication to tumor tissue is one of the most promising approaches to overcoming such obstacles. Optical biosensors are commonly used in clinical diagnostics, offering the advantage of continuous monitoring of biochemical reactions. The development of targeted medication delivery systems for a variety of illnesses, including cancer cells, is a potential area of nanomedicine. Researchers are concentrating on cancer cells because of their high rates of proliferation and resistance to conventional treatment techniques. .Lipid-based drug delivery employs nanoparticles to encapsulate and distribute medications to particular cells or tissues The present review is focused on personalized cancer vaccines are a promising immunotherapy targeting patient specific tumor neoantigens, and nanoparticles.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101060"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2025.101078
Ludovic Doucet , Camille Moreau-Bachelard , Laurent Mathiot , Olivier Kerdraon , Marie Robert , Julie Quintin , François Bocquet , Morgan Zenatri , Mario Campone , Jean-Sébastien Frenel
Background
Adjuvant trastuzumab emtansine (T-DM1) is the standard treatment for HER2-positive early breast cancer (EBC) patients who do not achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). Given the heterogeneity within this population, we analyzed long-term outcomes in non-pCR HER2-positive EBC patients who received adjuvant trastuzumab prior to the availability of the KATHERINE trial results
Methods
This single-center cohort study included all HER2-positive EBC patients treated with neoadjuvant chemotherapy at our hospital between 2006 and 2017. Kaplan–Meier and multivariable Cox regression models were employed to assess long-term invasive disease-free survival (iDFS) and overall survival (OS).
Results
This study included 103 patients, of which 67.0 % had a residual tumor size of ypT1, and 57.3 % had no residual tumor in the lymph nodes. The median follow-up was 9.3 years. At 3, 5, and 7 years, the iDFS rates were 78.3 %, 72.2 %, and 69.7 %, and the overall survival rates were 90.2 %, 83.3 %, and 79.8 %, respectively. Multivariate analysis identified ypT<2, ypN0, and estrogen receptor positivity as independent predictors of improved iDFS. Among patients with ypT<2, ypN0, and estrogen receptor-positive disease (34 out of 72 with estrogen receptor positivity), iDFS rates were notably high: 97 % (95 % CI: 91.3–100) at 3 years, and 90.9 % (95 % CI: 81.6–100) at both 5 and 7 years.
Conclusion
Patients without a pathologic complete response after neoadjuvant chemotherapy plus trastuzumab represent a heterogeneous group. Those with ypT<2, ypN0, and ER-positive residual disease may still achieve excellent iDFS and OS despite absence of adjuvant T-DM1.
{"title":"Favourable long-term outcomes in selected HER2-Positive early breast cancer patients without pathological complete response after neoadjuvant chemotherapy and trastuzumab: A pre–T-DM1 era cohort study","authors":"Ludovic Doucet , Camille Moreau-Bachelard , Laurent Mathiot , Olivier Kerdraon , Marie Robert , Julie Quintin , François Bocquet , Morgan Zenatri , Mario Campone , Jean-Sébastien Frenel","doi":"10.1016/j.ctarc.2025.101078","DOIUrl":"10.1016/j.ctarc.2025.101078","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant trastuzumab emtansine (T-DM1) is the standard treatment for HER2-positive early breast cancer (EBC) patients who do not achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). Given the heterogeneity within this population, we analyzed long-term outcomes in non-pCR HER2-positive EBC patients who received adjuvant trastuzumab prior to the availability of the KATHERINE trial results</div></div><div><h3>Methods</h3><div>This single-center cohort study included all HER2-positive EBC patients treated with neoadjuvant chemotherapy at our hospital between 2006 and 2017. Kaplan–Meier and multivariable Cox regression models were employed to assess long-term invasive disease-free survival (iDFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>This study included 103 patients, of which 67.0 % had a residual tumor size of ypT1, and 57.3 % had no residual tumor in the lymph nodes. The median follow-up was 9.3 years. At 3, 5, and 7 years, the iDFS rates were 78.3 %, 72.2 %, and 69.7 %, and the overall survival rates were 90.2 %, 83.3 %, and 79.8 %, respectively. Multivariate analysis identified ypT<2, ypN0, and estrogen receptor positivity as independent predictors of improved iDFS. Among patients with ypT<2, ypN0, and estrogen receptor-positive disease (34 out of 72 with estrogen receptor positivity), iDFS rates were notably high: 97 % (95 % CI: 91.3–100) at 3 years, and 90.9 % (95 % CI: 81.6–100) at both 5 and 7 years.</div></div><div><h3>Conclusion</h3><div>Patients without a pathologic complete response after neoadjuvant chemotherapy plus trastuzumab represent a heterogeneous group. Those with ypT<2, ypN0, and ER-positive residual disease may still achieve excellent iDFS and OS despite absence of adjuvant T-DM1.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101078"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2026.101095
Filip Ambrozkiewicz , Esraa Ali , Martina Bradova , Petr Slavík , Petr Martinek , Martin Svaton , Akseli Hemminki , Kari Hemminki
Limited DNA sequencing data on lung cancer (LC) patients are available from Eastern Europe where male smoking is commonest in Europe. As sequence analysis is the prerequisite for targeted therapy we provide such data from Czechia (CZ). Additionally, we present novel sequencing data for adenocarcinoma subtypes. Panel sequencing data on 1218 adenocarcinoma patients were available from a single histology laboratory for 2016 to 2024. The highest variant frequencies were observed for KRAS (51.6%), EGFR (18.8%) and TP53 (16.3%). Commonest types of variants were codon 12 mutations for KRAS, exon 21 L858R for EGFR and V600E BRAF. EGFR variants were more common in females (25.3% vs 11.5%). KRAS mutations were frequent in males (56.9% vs 46.9%), as were PIK3CA mutations (3.8% vs 1.9%). KRAS mutations were frequent in patients diagnosed below 70 years, whereas EGFR, PIK3CA and MET alterations were frequent in patients above age 70 years. As stage distinctions, high prevalence of KRAS mutations was found in early stage tumors (II and IIIA) and of TP53 mutations in stages IIIB and IV. As to adenocarcinoma subtypes, lepidic type showed a high frequency of EGFR variants. We could show differential distribution of gene variants by sex, diagnostic age, stage and subtype of adenocarcinoma. The data are in line with current literature that targeted treatment is being applied for selected LC patients in CZ. It can be expected that LC patients benefit from therapeutic and other clinical improvements, which however do not reduce the primary importance of anti-smoking campaigns.
来自东欧的肺癌（LC）患者的DNA测序数据有限，东欧男性吸烟是欧洲最常见的。由于序列分析是靶向治疗的先决条件，我们从捷克（CZ）提供了这些数据。此外，我们提出了新的腺癌亚型测序数据。2016年至2024年，1218名腺癌患者的小组测序数据来自单一组织学实验室。KRAS（51.6%）、EGFR（18.8%）和TP53（16.3%）的变异频率最高。最常见的变异类型是KRAS密码子12突变，EGFR外显子21 L858R突变和V600E BRAF突变。EGFR变异在女性中更为常见（25.3% vs 11.5%）。KRAS突变在男性中较为常见（56.9%对46.9%），PIK3CA突变在男性中较为常见（3.8%对1.9%）。KRAS突变常见于70岁以下的患者，而EGFR、PIK3CA和MET突变常见于70岁以上的患者。作为分期区分，KRAS突变在早期肿瘤（II期和IIIA期）中高发，TP53突变在IIIB期和IV期高发。在腺癌亚型中，lepidic型EGFR变异频率较高。我们可以显示基因变异在性别、诊断年龄、腺癌分期和亚型上的差异分布。数据与目前文献一致，CZ选择的LC患者正在应用靶向治疗。可以预期，LC患者受益于治疗和其他临床改善，然而，这并没有降低反吸烟运动的首要重要性。
{"title":"Mutational landscape of lung adenocarcinoma in Czechia","authors":"Filip Ambrozkiewicz , Esraa Ali , Martina Bradova , Petr Slavík , Petr Martinek , Martin Svaton , Akseli Hemminki , Kari Hemminki","doi":"10.1016/j.ctarc.2026.101095","DOIUrl":"10.1016/j.ctarc.2026.101095","url":null,"abstract":"<div><div>Limited DNA sequencing data on lung cancer (LC) patients are available from Eastern Europe where male smoking is commonest in Europe. As sequence analysis is the prerequisite for targeted therapy we provide such data from Czechia (CZ). Additionally, we present novel sequencing data for adenocarcinoma subtypes. Panel sequencing data on 1218 adenocarcinoma patients were available from a single histology laboratory for 2016 to 2024. The highest variant frequencies were observed for <em>KRAS</em> (51.6%), <em>EGFR</em> (18.8%) and <em>TP53</em> (16.3%). Commonest types of variants were codon 12 mutations for <em>KRAS</em>, exon 21 L858R for <em>EGFR</em> and V600E <em>BRAF. EGFR</em> variants were more common in females (25.3% vs 11.5%). <em>KRAS</em> mutations were frequent in males (56.9% vs 46.9%), as were <em>PIK3CA</em> mutations (3.8% vs 1.9%). <em>KRAS</em> mutations were frequent in patients diagnosed below 70 years, whereas <em>EGFR, PIK3CA</em> and <em>MET</em> alterations were frequent in patients above age 70 years. As stage distinctions, high prevalence of <em>KRAS</em> mutations was found in early stage tumors (II and IIIA) and of <em>TP53</em> mutations in stages IIIB and IV. As to adenocarcinoma subtypes, lepidic type showed a high frequency of <em>EGFR</em> variants. We could show differential distribution of gene variants by sex, diagnostic age, stage and subtype of adenocarcinoma. The data are in line with current literature that targeted treatment is being applied for selected LC patients in CZ. It can be expected that LC patients benefit from therapeutic and other clinical improvements, which however do not reduce the primary importance of anti-smoking campaigns.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101095"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2026.101108
Wen Zhang , Zhou Long , Xiaoli He , Xuemei Wu , Jian Wen , Dongfan Ye , Jia Chen , Guansong Wang
Introduction
Liver metastasis (LM) confers a poor prognosis in patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Although EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line treatment, the optimal approach for this high-risk subgroup remains uncertain. This study compared the efficacy and safety of EGFR-TKI monotherapy versus EGFR-TKI combined with chemotherapy in EGFR-mutant NSCLC patients with LM.
Patients and Methods
We retrospectively analyzed 98 patients with stage IV EGFR-mutant NSCLC and LM treated between 2020 and 2025. Fifty-nine patients received EGFR-TKI monotherapy, and 39 received EGFR-TKI plus platinum-based chemotherapy. Propensity score matching (PSM) was performed to balance baseline characteristics. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared by Cox regression. Safety profiles were analyzed according to CTCAE v5.0.
Results
After PSM, baseline characteristics were well balanced. The combination group achieved a higher objective response rate (59.0% vs 35.6%; P = .038), a higher disease control rate (100% vs 86.4%; P = .020), and a longer median PFS (14.0 vs 10.4 months; HR, 0.47; 95% CI, 0.26–0.86; P = .012). Median OS was 30.0 months with combination therapy versus 24.0 months with monotherapy (HR, 0.78; 95% CI, 0.39–1.55; P = .474). Severe (grade ≥3) adverse events were infrequent and comparable between groups, with no treatment-related deaths.
Conclusion
First-line EGFR-TKI plus chemotherapy significantly improved PFS and disease control without added toxicity, suggesting a promising therapeutic strategy for EGFR-mutant NSCLC with LM.
表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者发生肝转移（LM）预后较差。虽然EGFR酪氨酸激酶抑制剂（TKIs）是标准的一线治疗方法，但对于这一高危亚群的最佳方法仍不确定。本研究比较了EGFR-TKI单药治疗与EGFR-TKI联合化疗治疗EGFR-TKI突变NSCLC LM患者的疗效和安全性。患者和方法我们回顾性分析了2020年至2025年间治疗的98例IV期egfr突变型NSCLC和LM患者。59例患者接受EGFR-TKI单药治疗，39例患者接受EGFR-TKI联合铂类化疗。采用倾向评分匹配（PSM）来平衡基线特征。采用Kaplan-Meier法估计无进展生存期（PFS）和总生存期（OS），并采用Cox回归进行比较。根据CTCAE v5.0对安全性概况进行分析。结果经PSM后，基线特征平衡良好。联合治疗组的客观有效率更高（59.0% vs 35.6%, P = 0.038），疾病控制率更高（100% vs 86.4%, P = 0.020），中位PFS更长（14.0 vs 10.4个月；HR, 0.47; 95% CI, 0.26-0.86; P = 0.012）。联合治疗的中位OS为30.0个月，而单药治疗的中位OS为24.0个月（HR, 0.78; 95% CI, 0.39-1.55; P = 0.474）。严重（≥3级）不良事件很少发生，组间具有可比性，无治疗相关死亡。结论一线EGFR-TKI联合化疗可显著改善PFS和疾病控制，且不增加毒性，提示egfr -突变型NSCLC合并LM的治疗策略很有前景。
{"title":"Efficacy and safety of first-line EGFR-TKI combined with chemotherapy versus EGFR-TKI monotherapy in patients with EGFR-mutant non-small cell lung cancer and liver metastases: A propensity score–matched analysis","authors":"Wen Zhang , Zhou Long , Xiaoli He , Xuemei Wu , Jian Wen , Dongfan Ye , Jia Chen , Guansong Wang","doi":"10.1016/j.ctarc.2026.101108","DOIUrl":"10.1016/j.ctarc.2026.101108","url":null,"abstract":"<div><h3>Introduction</h3><div>Liver metastasis (LM) confers a poor prognosis in patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Although EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line treatment, the optimal approach for this high-risk subgroup remains uncertain. This study compared the efficacy and safety of EGFR-TKI monotherapy versus EGFR-TKI combined with chemotherapy in EGFR-mutant NSCLC patients with LM.</div></div><div><h3>Patients and Methods</h3><div>We retrospectively analyzed 98 patients with stage IV EGFR-mutant NSCLC and LM treated between 2020 and 2025. Fifty-nine patients received EGFR-TKI monotherapy, and 39 received EGFR-TKI plus platinum-based chemotherapy. Propensity score matching (PSM) was performed to balance baseline characteristics. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared by Cox regression. Safety profiles were analyzed according to CTCAE v5.0.</div></div><div><h3>Results</h3><div>After PSM, baseline characteristics were well balanced. The combination group achieved a higher objective response rate (59.0% vs 35.6%; <em>P</em> = .038), a higher disease control rate (100% vs 86.4%; <em>P</em> = .020), and a longer median PFS (14.0 vs 10.4 months; HR, 0.47; 95% CI, 0.26–0.86; <em>P</em> = .012). Median OS was 30.0 months with combination therapy versus 24.0 months with monotherapy (HR, 0.78; 95% CI, 0.39–1.55; <em>P</em> = .474). Severe (grade ≥3) adverse events were infrequent and comparable between groups, with no treatment-related deaths.</div></div><div><h3>Conclusion</h3><div>First-line EGFR-TKI plus chemotherapy significantly improved PFS and disease control without added toxicity, suggesting a promising therapeutic strategy for EGFR-mutant NSCLC with LM.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101108"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2025.101088
Samar M. Altoukhi , Moayad Alhumaid , Abdullah Olayan Alrasheed , Abdulaziz Suleiman Jastaniah , Faris K. Aljahdali , Abdulaziz Aida Alghashmari , Khaldon Alawliqi , Nora Trabulsi
Introduction
Breast surgery is often complicated by postoperative seroma, with incidence rates varying from 3% to 85% and no evidence-based prevention methods available. Fibrin glue plays an important role in promoting wound healing and reducing seroma formation. It reduces disruption of small blood and lymphatic vessels, thereby reducing seroma output and promoting effective hemostasis. Our aim was to evaluate the efficacy of fibrin sealant in reducing the incidence of seroma in patients undergoing surgery for breast cancer.
Methods
A research protocol was developed for this systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A comprehensive literature search was conducted using PubMed and Google Scholar. Medical subject heading terms used in the PubMed search included “fibrin tissue adhesive,” (“mastectomy,” or “breast surgery”) and “randomized controlled trial.”
Results
Sixteen studies were found with two primary findings: 1) Total drainage volume: Analysis of 13 studies showed a significant reduction in total drainage volume in patients treated with fibrin sealant compared with controls (mean difference, −2.18 mL; 95% confidence interval [CI]: −2.91, −1.46; P < 0.00001) and significant between studies. Diversity (I2=94%); 2). Incidence of seroma formation: An analysis of nine studies showed a 38% reduction in the odds of seroma formation with the use of fibrin sealant (odds ratio: 0.62; 95% CI: 0.40, 0.94; P = 0.02) and low heterogeneity (I2=6%).
Conclusion
This meta-analysis provides evidence supporting the use of fibrin sealants in breast cancer surgery, as seen by the reduction in drainage volume, suggesting potential benefits such as improved patient comfort and shorter hospital stay.
乳房手术常并发术后血清肿，其发生率从3%到85%不等，目前尚无循证预防方法。纤维蛋白胶在促进伤口愈合和减少血肿形成方面起着重要作用。它减少小血管和淋巴管的破坏，从而减少血肿输出，促进有效止血。我们的目的是评估纤维蛋白密封剂在降低乳腺癌手术患者血清肿发生率方面的疗效。方法：根据系统评价和荟萃分析指南的首选报告项目，为本系统评价制定了研究方案。使用PubMed和谷歌Scholar进行了全面的文献检索。在PubMed搜索中使用的医学主题标题包括“纤维蛋白组织粘合剂”（“乳房切除术”或“乳房手术”）和“随机对照试验”。结果：16项研究发现了两个主要发现：1)总引流量：13项研究的分析显示，与对照组相比，使用纤维蛋白密封剂的患者总引流量显著减少（平均差值为-2.18 mL； 95%可信区间[CI]: -2.91, -1.46; P < 0.00001），研究间差异有统计学意义。多样性(I2 = 94%);2）. 血肿形成的发生率：对9项研究的分析显示，使用纤维蛋白密封剂可使血肿形成的几率降低38%（优势比：0.62;95% CI: 0.40, 0.94; P = 0.02），且异质性低（I2=6%）。结论：这项荟萃分析提供了支持在乳腺癌手术中使用纤维蛋白密封剂的证据，因为引流量的减少表明了潜在的好处，如改善患者舒适度和缩短住院时间。
{"title":"Efficacy of fibrin sealants in preventing seroma formation following surgery for breast cancer: A systematic review and meta-analysis","authors":"Samar M. Altoukhi , Moayad Alhumaid , Abdullah Olayan Alrasheed , Abdulaziz Suleiman Jastaniah , Faris K. Aljahdali , Abdulaziz Aida Alghashmari , Khaldon Alawliqi , Nora Trabulsi","doi":"10.1016/j.ctarc.2025.101088","DOIUrl":"10.1016/j.ctarc.2025.101088","url":null,"abstract":"<div><h3>Introduction</h3><div>Breast surgery is often complicated by postoperative seroma, with incidence rates varying from 3% to 85% and no evidence-based prevention methods available. Fibrin glue plays an important role in promoting wound healing and reducing seroma formation. It reduces disruption of small blood and lymphatic vessels, thereby reducing seroma output and promoting effective hemostasis. Our aim was to evaluate the efficacy of fibrin sealant in reducing the incidence of seroma in patients undergoing surgery for breast cancer.</div></div><div><h3>Methods</h3><div>A research protocol was developed for this systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A comprehensive literature search was conducted using PubMed and Google Scholar. Medical subject heading terms used in the PubMed search included “fibrin tissue adhesive,” (“mastectomy,” or “breast surgery”) and “randomized controlled trial.”</div></div><div><h3>Results</h3><div>Sixteen studies were found with two primary findings: 1) Total drainage volume: Analysis of 13 studies showed a significant reduction in total drainage volume in patients treated with fibrin sealant compared with controls (mean difference, −2.18 mL; 95% confidence interval [CI]: −2.91, −1.46; <em>P</em> < 0.00001) and significant between studies. Diversity (I2=94%); 2). Incidence of seroma formation: An analysis of nine studies showed a 38% reduction in the odds of seroma formation with the use of fibrin sealant (odds ratio: 0.62; 95% CI: 0.40, 0.94; <em>P</em> = 0.02) and low heterogeneity (I2=6%).</div></div><div><h3>Conclusion</h3><div>This meta-analysis provides evidence supporting the use of fibrin sealants in breast cancer surgery, as seen by the reduction in drainage volume, suggesting potential benefits such as improved patient comfort and shorter hospital stay.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101088"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2026.101109
Jonathan W Lee , Xiao Jin , Stephanie Bogdan , Ayman Abou-Alfa , Josephine Chang , Michael Rafizadeh , Eric C Kang , Christine Garcia , Xi Kathy Zhou , Ashish Saxena
Epidermal growth factor receptor (EGFR) and programmed death ligand 1 (PD-L1) are cell surface proteins that interact in the context of immune evasion to promote cancer growth. Associations between PD-L1 expression level and clinico-pathologic features of EGFR mutated (EGFR-mt) non-small cell lung cancer (NSCLC), as well as response to Osimertinib (Osi) are unclear. We retrospectively analyzed clinical outcomes in patients with EGFR-mt Stage IV NSCLC treated with first line (1 L) Osi at three New York City (NYC) hospitals between 2018–2023. Progression-free survival (PFS) and overall survival (OS) were calculated using log rank test and cox proportional hazard model. 101 patients were included for final analysis. Demographics consistent with historic data. 52 patients (51 %) had PD-L1 negative disease and 11 patients (11 %) had PD-L1 ≥50 %. 56 patients (62 %) had brain metastases throughout their disease course. There was an 85 % response rate (RR) overall favoring PD-L1 negative disease (92 % vs 78 %) with a significantly lower odds of response for the PD-L1 positive group (Odds ratio (OR) 0.29; 95 % CI: 0.08–0.92, p = 0.046). In a multivariate analysis controlling for TP53 mutation status, OR 0.31, 05 % CI: 0.01–1.00, p = 0.063. PFS favored PD-L1 negative patients (22.7 vs 15.4 months) with hazard ratio (HR) of 1.49, p = 0.10. OS similarly favored PD-L1 negative patients (38.8 vs 31.4 months) with HR 1.53, p = 0.12. In a multivariate analysis controlling for TP53 mutations, PD-L1 positivity was associated with a trend towards reduced response to first line treatment with Osimertinib, as well as toward higher risk of progression and death
表皮生长因子受体（EGFR）和程序性死亡配体1 （PD-L1）是细胞表面蛋白，它们在免疫逃避的情况下相互作用，促进癌症的生长。PD-L1表达水平与EGFR突变（EGFR-mt）非小细胞肺癌（NSCLC）的临床病理特征以及对奥西替尼（Osi）的反应之间的关系尚不清楚。我们回顾性分析了2018-2023年在纽约市（NYC）三家医院接受一线（1l） Osi治疗的EGFR-mt IV期NSCLC患者的临床结果。采用log rank检验和cox比例风险模型计算无进展生存期（PFS）和总生存期（OS）。101例患者纳入最终分析。人口统计数据与历史数据一致。52例（51%）患者PD-L1阴性，11例（11%）患者PD-L1≥50%。56例（62%）患者在整个病程中出现脑转移。总体而言，PD-L1阴性疾病的缓解率（RR）为85% (92% vs 78%)，而PD-L1阳性组的缓解率明显较低(优势比（OR） 0.29；95% CI: 0.08-0.92, p = 0.046)。在控制TP53突变状态的多变量分析中，OR为0.31,05% CI为0.01-1.00,p = 0.063。PFS有利于PD-L1阴性患者（22.7 vs 15.4个月），风险比（HR）为1.49,p = 0.10。OS同样支持PD-L1阴性患者（38.8 vs 31.4个月），风险比为1.53,p = 0.12。在控制TP53突变的多变量分析中，PD-L1阳性与奥西替尼一线治疗反应降低的趋势以及更高的进展和死亡风险相关
{"title":"Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression","authors":"Jonathan W Lee , Xiao Jin , Stephanie Bogdan , Ayman Abou-Alfa , Josephine Chang , Michael Rafizadeh , Eric C Kang , Christine Garcia , Xi Kathy Zhou , Ashish Saxena","doi":"10.1016/j.ctarc.2026.101109","DOIUrl":"10.1016/j.ctarc.2026.101109","url":null,"abstract":"<div><div>Epidermal growth factor receptor (EGFR) and programmed death ligand 1 (PD-L1) are cell surface proteins that interact in the context of immune evasion to promote cancer growth. Associations between PD-L1 expression level and clinico-pathologic features of EGFR mutated (EGFR-mt) non-small cell lung cancer (NSCLC), as well as response to Osimertinib (Osi) are unclear. We retrospectively analyzed clinical outcomes in patients with EGFR-mt Stage IV NSCLC treated with first line (1 L) Osi at three New York City (NYC) hospitals between 2018–2023. Progression-free survival (PFS) and overall survival (OS) were calculated using log rank test and cox proportional hazard model. 101 patients were included for final analysis. Demographics consistent with historic data. 52 patients (51 %) had PD-L1 negative disease and 11 patients (11 %) had PD-L1 ≥50 %. 56 patients (62 %) had brain metastases throughout their disease course. There was an 85 % response rate (RR) overall favoring PD-L1 negative disease (92 % vs 78 %) with a significantly lower odds of response for the PD-L1 positive group (Odds ratio (OR) 0.29; 95 % CI: 0.08–0.92, <em>p</em> = 0.046). In a multivariate analysis controlling for TP53 mutation status, OR 0.31, 05 % CI: 0.01–1.00, <em>p</em> = 0.063. PFS favored PD-L1 negative patients (22.7 vs 15.4 months) with hazard ratio (HR) of 1.49, <em>p</em> = 0.10. OS similarly favored PD-L1 negative patients (38.8 vs 31.4 months) with HR 1.53, <em>p</em> = 0.12. In a multivariate analysis controlling for TP53 mutations, PD-L1 positivity was associated with a trend towards reduced response to first line treatment with Osimertinib, as well as toward higher risk of progression and death</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101109"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast cancer is the most prevalent cancer in women, with post-menopausal diagnoses more common than pre-menopausal. Risk factors for breast cancer include genetics and modifiable factors related to diet, behavior, and the environment. The objective of this study was to assess the impact of greenness and walkability on post-menopausal breast cancer risk.
Methods
Longitudinal cohort study design utilizing the Alberta Tomorrow Project cohort, with 15,536 post-menopausal women and 523 incident breast cancer cases over 12.6 years of follow-up. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard regression.
Results
The adjusted HR for an interquartile range (IQR = 0.1) increase in greenness measured within 1000 meters of the home location was 0.97 (95 % CI = 0.88, 1.07). Adjusted HRs for walkability ranged from 1.07 (95 % CI =0.77, 1.39) to 1.22 (95 % CI =0.90–1.60) for quintiles 2 through 5 (most walkable) in relation to quintile 1 (least walkable).
Conclusion
In this study the least walkable areas had lower breast cancer risk, after adjusting for social deprivation, age, and body mass index, although results were statistically non-significant except for an increased risk in quintile 4 (more walkable). Higher average greenness within 1000 meters of the home was not significantly associated with postmenopausal breast cancer risk after adjusting for smoking and social deprivation. More research in other settings is needed to advance knowledge on the association between the built environment and breast cancer risk.
乳腺癌是女性中最常见的癌症，绝经后诊断比绝经前更常见。乳腺癌的风险因素包括遗传和与饮食、行为和环境相关的可改变因素。这项研究的目的是评估绿化和步行对绝经后乳腺癌风险的影响。方法纵向队列研究设计利用阿尔伯塔明天项目队列，15536名绝经后妇女和523例乳腺癌病例随访12.6年。使用Cox比例风险回归估计风险比（hr）和95%置信区间（ci）。结果在离家1000米范围内测量的绿度增加的四分位数间（IQR = 0.1）调整后的HR为0.97 （95% CI = 0.88, 1.07）。2至5分位数（最适合步行）与1分位数（最不适合步行）的调整hr范围为1.07 （95% CI =0.77, 1.39）至1.22 （95% CI = 0.90-1.60）。在这项研究中，在调整了社会剥夺、年龄和体重指数之后，最不适合步行的地区患乳腺癌的风险更低，尽管结果在统计上没有显著意义，除了四分之一（更适合步行）的风险增加。在调整吸烟和社会剥夺因素后，家庭1000米内较高的平均绿化与绝经后乳腺癌风险没有显著关联。需要在其他环境中进行更多的研究，以提高对建筑环境与乳腺癌风险之间关系的认识。
{"title":"The association between greenness, walkability, and post-menopausal breast cancer risk in Alberta’s Tomorrow Project","authors":"Mohadeseh Ahmadi , Rachel A. Murphy , Maryam Darvishian , Trevor J.B. Dummer","doi":"10.1016/j.ctarc.2026.101121","DOIUrl":"10.1016/j.ctarc.2026.101121","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer is the most prevalent cancer in women, with post-menopausal diagnoses more common than pre-menopausal. Risk factors for breast cancer include genetics and modifiable factors related to diet, behavior, and the environment. The objective of this study was to assess the impact of greenness and walkability on post-menopausal breast cancer risk.</div></div><div><h3>Methods</h3><div>Longitudinal cohort study design utilizing the Alberta Tomorrow Project cohort, with 15,536 post-menopausal women and 523 incident breast cancer cases over 12.6 years of follow-up. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard regression.</div></div><div><h3>Results</h3><div>The adjusted HR for an interquartile range (IQR = 0.1) increase in greenness measured within 1000 meters of the home location was 0.97 (95 % CI = 0.88, 1.07). Adjusted HRs for walkability ranged from 1.07 (95 % CI =0.77, 1.39) to 1.22 (95 % CI =0.90–1.60) for quintiles 2 through 5 (most walkable) in relation to quintile 1 (least walkable).</div></div><div><h3>Conclusion</h3><div>In this study the least walkable areas had lower breast cancer risk, after adjusting for social deprivation, age, and body mass index, although results were statistically non-significant except for an increased risk in quintile 4 (more walkable). Higher average greenness within 1000 meters of the home was not significantly associated with postmenopausal breast cancer risk after adjusting for smoking and social deprivation. More research in other settings is needed to advance knowledge on the association between the built environment and breast cancer risk.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101121"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号